Systemic immune response induced by oxaliplatin-based neoadjuvant therapy favours survival without metastatic progression in high-risk rectal cancer

Erta Kalanxhi; Sebastian Meltzer; Jakob Vasehus Schou; Finn Ole Larsen; Svein Dueland; Kjersti Flatmark; Benny Vittrup Jensen; Knut Håkon Hole; Therese Seierstad; Kathrine Røe Redalen; Dorte Lisbet Nielsen; Anne Hansen Ree

doi:10.1038/s41416-018-0085-y

Systemic immune response induced by oxaliplatin-based neoadjuvant therapy favours survival without metastatic progression in high-risk rectal cancer

Erta Kalanxhi, Sebastian Meltzer, Jakob Vasehus Schou, Finn Ole Larsen, Svein Dueland, Kjersti Flatmark, Benny Vittrup Jensen, Knut Håkon Hole, Therese Seierstad, Kathrine Røe Redalen, Dorte Lisbet Nielsen, Anne Hansen Ree

Institut for Klinisk Medicin

14 Citationer (Scopus)

26 Downloads (Pure)

Abstract

Background: Systemic failure remains a challenge in rectal cancer. We investigated the possible systemic anti-tumour immune activity invoked within oxaliplatin-based neoadjuvant therapy. Methods: In two high-risk patient cohorts, we assessed the circulating levels of the fms-like tyrosine kinase 3 ligand (Flt3L), a factor reflecting both therapy-induced myelosuppression and activation of tumour antigen-presenting dendritic cells, at baseline and following induction chemotherapy and sequential chemoradiotherapy, both modalities containing oxaliplatin. The primary end point was progression-free survival (PFS). Results: In both cohorts, the median Flt3L level was significantly higher at completion of each sequential modality than at baseline. The 5-year PFS (most events being metastatic progression) was 68% and 71% in the two cohorts consisting of 33% and 52% T4 cases. In the principal cohort, a high Flt3L level following the induction chemotherapy was associated with low risk for a PFS event (HR: 0.15; P < 0.01). These patients also had available dose scheduling and toxicity data, revealing that oxaliplatin dose reduction during chemoradiotherapy, undertaken to maintain compliance to the radiotherapy protocol, was associated with advantageous PFS (HR: 0.47; P = 0.046). Conclusion: In high-risk rectal cancer, oxaliplatin-containing neoadjuvant therapy may promote an immune response that favours survival without metastatic progression.

Originalsprog	Engelsk
Tidsskrift	British Journal of Cancer
Vol/bind	118
Udgave nummer	10
Sider (fra-til)	1322-1328
Antal sider	7
ISSN	0007-0920
DOI	https://doi.org/10.1038/s41416-018-0085-y
Status	Udgivet - 1 maj 2018

FN’s Verdensmål

Dette resultat bidrager til følgende verdensmål

Adgang til dokumentet

10.1038/s41416-018-0085-yLicens: CC BY

Systemic immune response induced by oxaliplatin-based neoadjuvant therapy favours survival without metastatic progression in high-risk rectal cancerForlagets udgivne version, 387 KBLicens: CC BY

Citationsformater

Kalanxhi, E., Meltzer, S., Schou, J. V., Larsen, F. O., Dueland, S., Flatmark, K., Jensen, B. V., Hole, K. H., Seierstad, T., Redalen, K. R., Nielsen, D. L., & Ree, A. H. (2018). Systemic immune response induced by oxaliplatin-based neoadjuvant therapy favours survival without metastatic progression in high-risk rectal cancer. British Journal of Cancer, 118(10), 1322-1328. https://doi.org/10.1038/s41416-018-0085-y

Systemic immune response induced by oxaliplatin-based neoadjuvant therapy favours survival without metastatic progression in high-risk rectal cancer. / Kalanxhi, Erta; Meltzer, Sebastian; Schou, Jakob Vasehus et al.

I: British Journal of Cancer, Bind 118, Nr. 10, 01.05.2018, s. 1322-1328.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

Kalanxhi, E, Meltzer, S, Schou, JV, Larsen, FO, Dueland, S, Flatmark, K, Jensen, BV, Hole, KH, Seierstad, T, Redalen, KR, Nielsen, DL & Ree, AH 2018, 'Systemic immune response induced by oxaliplatin-based neoadjuvant therapy favours survival without metastatic progression in high-risk rectal cancer', British Journal of Cancer, bind 118, nr. 10, s. 1322-1328. https://doi.org/10.1038/s41416-018-0085-y

@article{848df104ee4e4eebab57063bc9e79643,

title = "Systemic immune response induced by oxaliplatin-based neoadjuvant therapy favours survival without metastatic progression in high-risk rectal cancer",

abstract = "Background: Systemic failure remains a challenge in rectal cancer. We investigated the possible systemic anti-tumour immune activity invoked within oxaliplatin-based neoadjuvant therapy. Methods: In two high-risk patient cohorts, we assessed the circulating levels of the fms-like tyrosine kinase 3 ligand (Flt3L), a factor reflecting both therapy-induced myelosuppression and activation of tumour antigen-presenting dendritic cells, at baseline and following induction chemotherapy and sequential chemoradiotherapy, both modalities containing oxaliplatin. The primary end point was progression-free survival (PFS). Results: In both cohorts, the median Flt3L level was significantly higher at completion of each sequential modality than at baseline. The 5-year PFS (most events being metastatic progression) was 68% and 71% in the two cohorts consisting of 33% and 52% T4 cases. In the principal cohort, a high Flt3L level following the induction chemotherapy was associated with low risk for a PFS event (HR: 0.15; P < 0.01). These patients also had available dose scheduling and toxicity data, revealing that oxaliplatin dose reduction during chemoradiotherapy, undertaken to maintain compliance to the radiotherapy protocol, was associated with advantageous PFS (HR: 0.47; P = 0.046). Conclusion: In high-risk rectal cancer, oxaliplatin-containing neoadjuvant therapy may promote an immune response that favours survival without metastatic progression.",

author = "Erta Kalanxhi and Sebastian Meltzer and Schou, {Jakob Vasehus} and Larsen, {Finn Ole} and Svein Dueland and Kjersti Flatmark and Jensen, {Benny Vittrup} and Hole, {Knut H{\aa}kon} and Therese Seierstad and Redalen, {Kathrine R{\o}e} and Nielsen, {Dorte Lisbet} and Ree, {Anne Hansen}",

year = "2018",

month = may,

day = "1",

doi = "10.1038/s41416-018-0085-y",

language = "English",

volume = "118",

pages = "1322--1328",

journal = "The British journal of cancer. Supplement",

issn = "0007-0920",

publisher = "nature publishing group",

number = "10",

}

TY - JOUR

T1 - Systemic immune response induced by oxaliplatin-based neoadjuvant therapy favours survival without metastatic progression in high-risk rectal cancer

AU - Kalanxhi, Erta

AU - Meltzer, Sebastian

AU - Schou, Jakob Vasehus

AU - Larsen, Finn Ole

AU - Dueland, Svein

AU - Flatmark, Kjersti

AU - Jensen, Benny Vittrup

AU - Hole, Knut Håkon

AU - Seierstad, Therese

AU - Redalen, Kathrine Røe

AU - Nielsen, Dorte Lisbet

AU - Ree, Anne Hansen

PY - 2018/5/1

Y1 - 2018/5/1

N2 - Background: Systemic failure remains a challenge in rectal cancer. We investigated the possible systemic anti-tumour immune activity invoked within oxaliplatin-based neoadjuvant therapy. Methods: In two high-risk patient cohorts, we assessed the circulating levels of the fms-like tyrosine kinase 3 ligand (Flt3L), a factor reflecting both therapy-induced myelosuppression and activation of tumour antigen-presenting dendritic cells, at baseline and following induction chemotherapy and sequential chemoradiotherapy, both modalities containing oxaliplatin. The primary end point was progression-free survival (PFS). Results: In both cohorts, the median Flt3L level was significantly higher at completion of each sequential modality than at baseline. The 5-year PFS (most events being metastatic progression) was 68% and 71% in the two cohorts consisting of 33% and 52% T4 cases. In the principal cohort, a high Flt3L level following the induction chemotherapy was associated with low risk for a PFS event (HR: 0.15; P < 0.01). These patients also had available dose scheduling and toxicity data, revealing that oxaliplatin dose reduction during chemoradiotherapy, undertaken to maintain compliance to the radiotherapy protocol, was associated with advantageous PFS (HR: 0.47; P = 0.046). Conclusion: In high-risk rectal cancer, oxaliplatin-containing neoadjuvant therapy may promote an immune response that favours survival without metastatic progression.

AB - Background: Systemic failure remains a challenge in rectal cancer. We investigated the possible systemic anti-tumour immune activity invoked within oxaliplatin-based neoadjuvant therapy. Methods: In two high-risk patient cohorts, we assessed the circulating levels of the fms-like tyrosine kinase 3 ligand (Flt3L), a factor reflecting both therapy-induced myelosuppression and activation of tumour antigen-presenting dendritic cells, at baseline and following induction chemotherapy and sequential chemoradiotherapy, both modalities containing oxaliplatin. The primary end point was progression-free survival (PFS). Results: In both cohorts, the median Flt3L level was significantly higher at completion of each sequential modality than at baseline. The 5-year PFS (most events being metastatic progression) was 68% and 71% in the two cohorts consisting of 33% and 52% T4 cases. In the principal cohort, a high Flt3L level following the induction chemotherapy was associated with low risk for a PFS event (HR: 0.15; P < 0.01). These patients also had available dose scheduling and toxicity data, revealing that oxaliplatin dose reduction during chemoradiotherapy, undertaken to maintain compliance to the radiotherapy protocol, was associated with advantageous PFS (HR: 0.47; P = 0.046). Conclusion: In high-risk rectal cancer, oxaliplatin-containing neoadjuvant therapy may promote an immune response that favours survival without metastatic progression.

U2 - 10.1038/s41416-018-0085-y

DO - 10.1038/s41416-018-0085-y

M3 - Journal article

C2 - 29695770

SN - 0007-0920

VL - 118

SP - 1322

EP - 1328

JO - The British journal of cancer. Supplement

JF - The British journal of cancer. Supplement

IS - 10

ER -

Systemic immune response induced by oxaliplatin-based neoadjuvant therapy favours survival without metastatic progression in high-risk rectal cancer

Abstract

FN’s Verdensmål

Adgang til dokumentet

Fingeraftryk

Citationsformater